Secondary analysis of the VACIMRA trial (one centre, 83 analysed at 12 months): in early RA, delaying MTX by 1 month after PCV13 vaccination vs starting immediately gave no significant difference in 1-year remission or low disease activity; X-ray progression was similar.
Secondary analysisn = 100
Than et al. One-month delay in MTX initiation on RA outcomes: 1-year ancillary analysis of the VACIMRA trial